Red light emitting diode as an adjuvant treatment for epidermal growth factor receptor inhibitors-induced paronychia

J Dermatolog Treat. 2022 Jun;33(4):1990-1994. doi: 10.1080/09546634.2021.1927950. Epub 2021 May 24.

Abstract

We evaluated the efficacy and safety of red light LED as an adjuvant treatment for epidermal growth factor receptor inhibitor-induced paronychia. Eight patients were recruited in this randomized, single-blinded controlled trial. They were randomized to receive red-light on one hand or foot 2-3 times/week for 6 weeks while the contralateral side served as controls. The standard treatments were continued. Erythema and lesion elevation observed by Anthera® 3D, severity and pain scores were obtained at weeks 0, 2, 4, 6, and 8. The red light group showed significantly lower erythema, severity, and pain scores at weeks 4, 6, and 8. The elevation was significantly lower in the red light group at every follow-up visit. No adverse events occurred. Red light therapy may be an option as adjunctive treatment for EGFRi-induced paronychia.

Keywords: EGFRi; Epidermal growth factor receptor inhibitors; LED; paronychia; red light; treatment.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • ErbB Receptors / antagonists & inhibitors
  • Erythema / etiology
  • Erythema / therapy
  • Humans
  • Pain / etiology
  • Paronychia* / chemically induced
  • Paronychia* / complications
  • Paronychia* / therapy
  • Phototherapy* / methods
  • Protein Kinase Inhibitors* / adverse effects
  • Single-Blind Method

Substances

  • Protein Kinase Inhibitors
  • ErbB Receptors